Oral inhibition 23 items
Muvalaplin, the small-molecule inhibitor of Lp(a) assembly.
Trials, agents, guidance
Studies
- KRAKEN: oral muvalaplin lowers Lp(a) by 82 to 86 percent on an intact-particle assay (Nicholls et al., JAMA 2025)
- Muvalaplin, the first oral inhibitor of Lp(a) formation: phase 1 (Nicholls et al., JAMA 2023)
- Olpasiran tops a network meta-analysis of 51 trials (17,810 patients) ranking Lp(a)-lowering therapies against PCSK9 inhibitors (Diabetes Obes Metab 2026)
- Olpasiran leads a network meta-analysis of 25 trials (7,715 patients) ranking every Lp(a)-lowering agent (Pharmacol Res 2026)
- Nature paper unveils muvalaplin, an oral small molecule that blocks the very first step of Lp(a) particle assembly (Nature 2024)
- Five late-stage RNA and small-molecule Lp(a) therapies near approval, from pelacarsen to muvalaplin (Curr Atheroscler Rep 2026)
- Twenty clinical trials map the Lp(a)-lowering therapeutic landscape across three drug classes, review (J Clin Med 2026)
- From apheresis to CRISPR: review maps every Lp(a)-lowering therapy in development (Curr Atheroscler Rep 2026)
- Pelacarsen, olpasiran, lepodisiran and zerlasiran cut Lp(a) by 80 to almost 100%, with phase 3 outcomes readouts possible in 2026, pipeline review finds (Expert Opin Pharmacother 2025)
- Muvalaplin cut Lp(a) by up to 85.5% on a novel intact assay in the phase 2 KRAKEN trial, review of the first oral Lp(a) inhibitor finds (Expert Opin Investig Drugs 2025)
- A new isoform-insensitive Lp(a) particle assay reveals commercial assays underestimated muvalaplin's efficacy (J Lipid Res 2025)
- Muvalaplin cuts Lp(a) by up to 86% in phase 2 without injection-site reactions, review (Cardiovasc Hematol Disord Drug Targets 2026)
- Pirillo and Catapano review how Lp(a)-targeted RNA therapies and the oral inhibitor muvalaplin are reshaping cardiovascular risk assessment (Eur J Intern Med 2025)
- From GalNAc-conjugated injectables to the oral inhibitor muvalaplin, review surveys the Lp(a)-lowering pipeline and calls for an isoform-independent assay standard (Pharmaceuticals (Basel) 2025)
- Nicholls and colleagues review muvalaplin, the first oral Lp(a)-lowering agent, as it enters cardiovascular outcome testing (Curr Opin Lipidol 2024)
- Nicholls reviews mipomersen, pelacarsen, RNAi agents and muvalaplin as guidelines already push universal Lp(a) measurement (Drugs 2024)
- Lp(a) rises as kidney function declines, adding unaddressed cardiovascular risk in CKD, review (Cardiorenal Med 2026)
Video and podcasts